Lymphoma Clinical Trial
Official title:
The Pre-Emptive Use of Recipient-Derived Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation After Allogeneic Stem Cell Transplantation
The goal of this clinical research study is to learn if giving cytotoxic T lymphocytes (CTLs) can help control CMV when it reactivates (becomes active again) in patients who receive an allogeneic stem cell transplant. Researchers also want to learn about the safety of giving CTLs to patients who have had a stem cell transplant.
The CTLs:
Blood (about 34 tablespoons) will be drawn 1 time. The blood will be frozen and stored in a
laboratory at MD Anderson for future use to make the CTLs. If CMV comes back after your
transplant, the blood will be used to create CTLs. To create CTLs, blood cells are grown in
the laboratory and trained to kill CMV. If the blood is not used to make the CTLs within 3
years, it will be destroyed.
CTL Administration:
If your CMV becomes active after your stem cell transplant, you will receive the CTLs through
a needle in your vein over 1-5 minutes one time, within 72 hours after CMV becomes active
again. Before you receive the CTLs, you will receive Benadryl (diphenhydramine) and Tylenol
(acetaminophen) by mouth to help reduce the risk of side effects. This can be done in either
the hospital (if not yet discharged after your transplant) or in the outpatient clinic (if
you are discharged).
Your vital signs will be monitored at the end of the infusion, and then at 30 and 60 minutes
after the infusion. Your oxygen level will be measured by pulse oximetry. For this test, a
clothespin-shaped clip will be placed on your finger for at least 30 minutes. If you are an
outpatient, you will remain in the clinic for at least 1 hour after the CTL infusion.
If the CMV does not become active again after your stem cell transplant, you will not receive
the CTL infusion.
Study Visits:
If the CMV does not become active again after your stem cell transplant, you will not receive
the CTL infusion and your follow-up care will be done as per post-transplant standard of
care.
If you receive the CTL infusion, you will have the tests/procedures listed below.
Within 48 hours before the CTL infusion:
- You will have a physical exam.
- Blood (about 6 tablespoons) will be drawn for routine tests and to check your kidney and
liver function. Part of blood draw will be used for a pregnancy test for women who are
able to become pregnant. To take part in this study, you must not be pregnant.
Once a week for 4 weeks, blood (about 4-8 tablespoons) will be drawn to check the level of
CMV infection in your body. This may be done more often, if you doctor thinks it is needed.
About 1, 2, 3, and 4 weeks, and then about 3, 6, and 12 months after the CTL infusion:
- You will have a physical exam.
- Blood (about 4 tablespoons) will be drawn for routine tests and to check your kidney and
liver function.
Blood (about 4 tablespoons) will be drawn for tests to learn more about the way the CTLs are
working and how long they last in the body. This blood will be drawn before the CTL infusion,
and then about 2 weeks, 4 weeks, 3 months, and 6 months after the CTL infusion. If possible,
the blood needed for these tests will be collected during blood draws for routine tests so
that no additional needle sticks will be needed.
Follow-Up Visits:
Once a week for 6 weeks, and then about 3, 6, 9, and 12 months after the CTL infusion, you
will be checked for signs of graft-versus-host disease (GVHD) at every clinic visit. You were
told about GVHD at the time of being prepared for transplant.
Length of Study:
Your participation on this study will end after your last follow-up visit about 12 months
after the CTL infusion.
This is an investigational study. The use of CTLs to treat CMV infection is not FDA approved.
At this time, CTLs are only being used to treat infections in research studies.
Up to 105 patients will take part in this study. All will be enrolled at MD Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |